Wed, December 8, 2010
[ Wed, Dec 08th 2010 ]: Market Wire
Alnylam to Webcast Presentation at 2010 Deutsche Bank BioFEST
[ Wed, Dec 08th 2010 ]: Market Wire
El programa Give for Real de Mannatech permite qu .. na importante donacin a la Fundacin Vamos M©xico
[ Wed, Dec 08th 2010 ]: Market Wire
ImmunoCellular Therapeuticsa? Chief Executive Off .. resent at Prestigious Cancer Stem Cell Conference
[ Wed, Dec 08th 2010 ]: Market Wire
St. Jude Medical Advances Integration of Electrop .. Equipment with Launch of Several New Technologies
[ Wed, Dec 08th 2010 ]: Market Wire
Alkermes Announces Results from Phase 2 Study of ALKS 33 in Alcohol Dependence
[ Wed, Dec 08th 2010 ]: Market Wire
CHINA HEALTH LABS &; DIAGNOSTICS LTD. ANNOUNCES R .. CH &; DEVELOPMENT AGREEMENT WITH CHINESE MILITARY
[ Wed, Dec 08th 2010 ]: Market Wire
CIGNA Announces Completion of Tender Offer for Any and All of Its 8.50% Senior Notes Due 2019
[ Wed, Dec 08th 2010 ]: Market Wire
Cubist Pharmaceuticals to Present at December Investor Conference
[ Wed, Dec 08th 2010 ]: Market Wire
Clinical Data, Inc. Announces Vilazodone Data Pre .. at American Society of Health System Pharmacists
[ Wed, Dec 08th 2010 ]: Market Wire
CytRx Announces Compliance with NASDAQ's Minimum Bid Requirement
[ Wed, Dec 08th 2010 ]: Market Wire
InSite Vision to Host Investor Conference Call Introducing New CEO Timothy Ruane
[ Wed, Dec 08th 2010 ]: Market Wire
Emergent BioSolutions to Webcast Presentation at JPMorgan Healthcare Conference
[ Wed, Dec 08th 2010 ]: Market Wire
Une ©tude observationnelle ne d©montre aucune i .. s la leuc©mie my©lode aigu avec REVLIMID® chez
[ Wed, Dec 08th 2010 ]: Market Wire
Beobachtungsstudie zeigt kein hheres Auftreten de .. atischen Leukmie mit REVLIMID® bei Patienten mit
Tue, December 7, 2010
[ Tue, Dec 07th 2010 ]: Market Wire
Bijgewerkte klinische resultaten van fase-3 onder .. g met REVLIMID tonen statistisch significante ver
[ Tue, Dec 07th 2010 ]: Market Wire
L'©tude de phase III ©valuant le traitement au .. tant des risques ©lev©s de my©lome multiple co
[ Tue, Dec 07th 2010 ]: Market Wire
Phase-III-Studie zur Evaluierung von REVLIMID® i .. ines schwelenden multiplen Myeloms ergab statisti
[ Tue, Dec 07th 2010 ]: Market Wire
Updated Clinical Results from REVLIMID® Continuo .. how Statistically Significant Improvement in Prog
[ Tue, Dec 07th 2010 ]: Market Wire
Emergency Medical Services Announces Ambulance Company Acquisition
[ Tue, Dec 07th 2010 ]: Market Wire
Abiomed Ends Protect II Study and Announces Inter .. led Clinical Analysis to Be Presented at ACC 2011
[ Tue, Dec 07th 2010 ]: Market Wire
Apricus Biosciences lance une s©rie de vid©os  .. ment nouvellement approuv© pour le traitement de
[ Tue, Dec 07th 2010 ]: Market Wire
Geron Corporation Announces Proposed Public Offering of Common Stock
[ Tue, Dec 07th 2010 ]: Market Wire
Neue klinische Daten aus einer Open-Label-Schlsse .. uierung von ISTODAX® fr Patienten mit peripherem
[ Tue, Dec 07th 2010 ]: Market Wire
Doorlopende behandeling met REVLIMID bij patinten .. tologe stamceltransplantatie gevalueerd door Inte
[ Tue, Dec 07th 2010 ]: Market Wire
Apricus Biosciences lancia una serie di video edu .. temente approvato contro la disfunzione erettile,
[ Tue, Dec 07th 2010 ]: Market Wire
Pr©sentation de donn©es sur le traitement au RE .. y©lome multiple, ©valuant les taux de survie av
[ Tue, Dec 07th 2010 ]: Market Wire
Dauerbehandlung von Multiplen-Myelom-Patienten mi .. ine autologe Stammzellentransplantation durch Int
[ Tue, Dec 07th 2010 ]: Market Wire
Beurteilung der Dauerbehandlung mit REVLIMID® be .. om nach autologer Stammzellentransplantation in P
[ Tue, Dec 07th 2010 ]: Market Wire
Il trattamento continuo con REVLIMID® sui pazien .. a seguito di trapianto di cellule staminali auto
[ Tue, Dec 07th 2010 ]: Market Wire
I risultati clinici aggiornati dello studio di fa .. trattamento continuo con REVLIMID® mostrano un m
[ Tue, Dec 07th 2010 ]: Market Wire
Gegevens uit drie presentaties evalueren klinisch .. n eerder behandeld meervoudig myeloom tijdens ASH
Mon, December 6, 2010
[ Mon, Dec 06th 2010 ]: Market Wire
Valeant Pharmaceuticals International, GlaxoSmithKline, Pfizer, UCB Pharma and Johnson & Johnson
[ Mon, Dec 06th 2010 ]: Market Wire
Micrometa?s Blinatumomab Produces High Objective .. trum of Relapsed Non-Hodgkina?s Lymphoma Patients
[ Mon, Dec 06th 2010 ]: Market Wire
Klinische Daten zur Evaluierung von oral verabrei .. Rituximab oder nach einer Rituximab-Kombinationst
[ Mon, Dec 06th 2010 ]: Market Wire
REPEAT/ ARIADa?s Ponatinib Shows Clinical Evidenc .. emic Activity in Patients with Drug-Resistant CML
[ Mon, Dec 06th 2010 ]: Market Wire
Geron Presents Clinical Data on Its Telomerase Va .. t the 2010 American Society of Hematology Meeting
[ Mon, Dec 06th 2010 ]: Market Wire
Incyte Presents Positive Long-Term Results from O .. 18424 in Advanced Polycythemia Vera (PV) and Esse
[ Mon, Dec 06th 2010 ]: Market Wire
Cubist Pharmaceuticals Files Citizen Petition with Food and Drug Administration
[ Mon, Dec 06th 2010 ]: Market Wire
New Studies Support Therapeutic Potential of Comp .. Discovered Target for Multiple Myeloma Treatment
[ Mon, Dec 06th 2010 ]: Market Wire
Biogen Idec e Swedish Orphan Biovitrum annunciano .. lla proteina di fusione ricombinante a lungo term
[ Mon, Dec 06th 2010 ]: Market Wire
Biogen Idec und Swedish Orphan Biovitrum melden e .. enden rekombinanten Faktor-VIII-Fc-Fusionsprotein
[ Mon, Dec 06th 2010 ]: Market Wire
Biogen Idec et Swedish Orphan Biovitrum annoncent .. patient dans le cadre da?un essai mondial da?homo
[ Mon, Dec 06th 2010 ]: Market Wire
ZIOPHARM Presents New Darinaparsin Preclinical Lymphoma Data at ASH Annual Meeting
[ Mon, Dec 06th 2010 ]: Market Wire
Continuous Treatment with REVLIMID® for Patients .. ng Autologous Stem Cell Transplant Evaluated by I
[ Mon, Dec 06th 2010 ]: Market Wire
Alexion Reports Results from First Clinical Trial .. Cancer Antibody Samalizumab at ASH Annual Meeting
[ Mon, Dec 06th 2010 ]: Market Wire
Updated Results from FOLOTYN® Phase 1 Dose Findi .. in Relapsed or Refractory Cutaneous T-Cell Lymph
[ Mon, Dec 06th 2010 ]: Market Wire
Phase III Study Showed Rituxan® for Initial Use .. yed the Need for Additional Therapy in People wit
[ Mon, Dec 06th 2010 ]: Market Wire
Seattle Genetics and Millennium Report Positive D .. ntuximab Vedotin (SGN-35) in Relapsed or Refracto

Presentazione all'ASH dei dati derivati da tre presentazioni per la valutazione dei benefici clinici del pomalidomide nel mielo

BOUDRY, Svizzera--([ BUSINESS WIRE ])--Celgene International Srl (NASDAQ: CELG) ha annunciato oggi la valutazione del suo prossimo composto IMiD® il pomalidomide, in tre diversi studi sperimentali di pazienti affetti da mieloma multiplo recidivante o refrattario in seguito a trattamenti precedenti a base di lenalidomide, talidomide e bortezomib. I dati clinici sono stati presentati in occasione del 52 incontro annuale della Societ Americana di Ematologia (ASH) a Orlando, in Florida.

Compendio n. 859 a" Studio di Fase 2 di 2 modalit di pomalidomide (CC4047) pi una dose ridotta di desametasone come terapia per il mieloma multiplo recidivante, IFM 2009-02

Il testo originale del presente annuncio, redatto nella lingua di partenza, la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodit del lettore e devono rinviare al testo in lingua originale, che l'unico giuridicamente valido.